Melanoma gene signature

Details Melanoma gene signature Melanoma gene signature

2007-09-07

2009-11-10

Aeder, Sean E (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

Reexamination Certificate

active

07615349

ABSTRACT:
Methods and compositions for evaluating gene expression in melanoma samples are provided herein.

REFERENCES:
patent: 7056674 (2006-06-01), Baker et al.
patent: 7081340 (2006-07-01), Baker et al.
patent: 7171311 (2007-01-01), Dai et al.
patent: 7247426 (2007-07-01), Yakhini et al.
patent: 2006/0183141 (2006-08-01), Change et al.
patent: 2007/0154889 (2007-07-01), Wang et al.
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Greenbaum et al. (Genome Biology, 2003, vol. 4, Issue 9, pp. 117.1-117.8).
Glas et al., “Converting a breast cancer microarray signature into a high-throughput diagnostic test,”BMC Genomics, vol. 7:278-288 (2006).
Ai et al., “Epigenetic Silencing of the Tumor Suppressor Cystatin M Occurs during Breast Cancer Progression,”Cancer Research, vol. 66:7900-7909 (2006).
An et al., “Deletion of tumor suppressor genes in Chinese non-small cell lung cancer,”Cancer Letters, vol. 184:189-195 (2002).
Balch et al. “A New American Joint Committee on Cancer Staging System for Cutaneous Melanoma,”Cancer, vol. 88:1484-1491 (2000).
Balch et al., “Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma,”Journal of Clinical Oncology, vol 19:3635-3648 (2001).
Balch et al., “Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System,”Joint of Clinical Oncology, vol. 19:3622-3634 (2001).
Barrow et al., “Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage,”Clin. Can. Res., vol. 12:764-771 (2006).
Bauskin et al., “Role of Macrophage Inhibitory Cytokine-1 in Tumorigenesis and Diagnosis of Cancer,”Cancer Research, vol. 66:4983-4986 (2006).
Baylin et al., “Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia,”Adv. in Cancer Res, vol. 72:141-196 (1998).
Bittner et al., “Molecular classification of cutaneous malignant melanoma by gene expression profiling,”Nature, vol. 406:536-540 (2000).
Brasseur et al. “Expression ofMageGenes in Primary and Metastatic Cutaneous Melanoma,”Int. J. Cancer, vol. 63:375-380 (1995).
Cascinelli et al., “Sentinel Lymph Node Biopsy in Cutaneous Melanoma: The WHO Melanoma Program Experience,”Annals of Surgical Oncology, vol. 7:469-474 (2000).
Chen et al., “Decreased PITX1 homeobox gene expression in human lung cancer,”Lung Cancer, vol. 55:287-294 (2007).
Coppola et al., “Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies,”Clin. Can. Res., vol. 10:184-190 (2004).
DeRisi et al., “Use of a cDNA microarray to analyze gene expression patterns in human cancer,”Nature Genetics, vol. 14:457-460 (1996).
Dobbin et al, “Interlaboratory Comparability Study of Cancer Gene Expression Analysis Using Oligonucleotide Microarrays,”Clinical Cancer Research, vol. 11:565-572 (2005).
Eton et al., “Prognostic Factors for Survival of Patients Treated Systemically for Disseminated Melanoma,”Journal of Clinical Oncology, vol. 16:1103-1111 (1998).
Fujiwara et al., “Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor beta gene,”Oncogene, vol. 10:891-895 (1995).
Gallagher et al., “Multiple markers for melanoma progression regulated by DNA methylation: Insights from transcriptomic studies,”Carcinogenesis, vol. 26:1856-1867 (2005).
Garraway et al., “Integrative genomic anlayses identifyMITFas a lineage survival oncogene amplified in malignant melanoma,”Nature, vol. 436:117-122 (2005).
Golub et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring,”Science, vol. 286:531-537 (1999).
Haddad et al., “The Progression of Melanoma Nodal Metastasis is Dependent on Tumor Thickness of the Primary Lesion,”Annals of Surgical Oncology, vol. 6:144-149 (1999).
Hanahan et al., “The Hallmarks of Cancer,”Cell, vol. 100:57-70 (2000).
Haqq et al., “The gene expression signatures of melanoma progression,”Proc. Natl. Acad. Sci. U. S. A., vol. 102:6092-6097 (2005).
Harbig et al., “A sequence-based identification of the genes detected by probesets on the Affymetrix U133 plus 2.0 array,”Nucleic Acids Research, vol. 33:e31 (2005).
Herman et al., “Gene Silencing in Cancer in Association with Promoter Hypermethylation,”N. Engl. J. Med., vol. 349:2042-2054 (2003).
Hodi, “Well-Defined Melanoma Antigens as Progression Markers for Melanoma: Insights into Differential Expression and Host Response Based on Stage,”Clin. Can. Res., vol. 12:673-678 (2006).
Jaeger et al., “Gene Expression Signatures for Tumor Progression, Tumor Subtype, and Tumor Thickness in Laser-Microdissected Melanoma Tissues,”Clin. Can. Res., vol.13:806-815 (2007).
Jemal et al., “Cancer Statistics, 2007,”C.A. Cancer J. Clin., vol. 57:43-66 (2007).
Jensen et al., “Down-Regulation of Pro-Apoptotic Genes is an Early Event in the Progression of Malignant Melanoma,”Annals of Surgical Oncology, vol. 14:1416-1423 (2007).
Kim et al., “Epigenomic Profiling Reveals Novel and Frequent Targets of Aberrant DNA Methylation-Mediated Silencing in Malignant Glioma,”Cancer Res., vol. 66:7490-7501 (2006).
Kolfschoten et al., “A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity,”Cell, vol. 121:849-858 (2005).
Lerebours et al., “Fine Deletion Mapping of Chromosome 8p in Non-Small-Cell Lung Carcinoma,”Int. J. Cancer, vol. 81:854-858 (1999).
Levy et al., “MITF: master regulator of melanocyte development and melanoma oncogene,”Trends Molecular Medicine, vol. 12:406-414 (2006).
Li et al., “Model-based analysis of oligunucleotide arrays: Expression index computation and outlier detection,”Proc. Natl. Acad. Sci. U.S.A., vol. 98:31-36 (2001).
Lord et al.,. “IncreasedCDX2and decreasedPITX1homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma,”Surgery, vol. 138:924-931 (2005).
McGill et al., “c-Met Expression is Regulated by Mitf in the Melanocyte Lineage,”J. Biol. Chem., vol. 281:10365-10373 (2006).
Momparler, “Cancer epigenetics,”Oncogene, vol. 22:6479-6483 (2003).
Muthusamy et al., “Epigenetic Silencing of Novel Tumor Suppressors in Malignant Melanoma,”Cancer Res., vol. 66:11187-11193 (2006).
Riker, “Isolation and Culture of Melanoma Cell Lines,”Cancer Cell Culture: Methods and Protocols, Totowa: Humana Press, vol. 88:93-100 (2004).
Riker et al., Development and Characterization of Melanoma Cell Lines Established by Fine Needle Aspiration Biopsy: Advances in the Monitoring of Patients with Metastatic Melanoma,Cancer Detection and Prevention, vol. 23:387-396 (1999).
Rivenbark et al., “DNA methylation-dependent silencing of CST6 in human breast cancer cell lines,”Laboratory Investigation, vol. 86:1233-1242 (2006).
Seitz et al., “Genetic Background of Different Cancer Cell Lines Influences the Gene Set Involved in Chromosome 8 Mediated Breast Tumor Suppression,”Genes, Chromosomes&Cancer, vol. 45:612-627 (2006).
Seykora et al., “Gene Expression Profiling of Melanocytic Lesions,”The American Journal of Dermatopathology, vol. 25:6-11 (2003).
Smith et al., “Whole-Genome Expression Profiling of the Melanoma Progression Pathway Reveals Marked Molecular Differences Between Nevi/Melanoma in Situ and Advanced-Stage Melanomas,”Cancer Biology&Therapy, vol. 4:1018-1029 (2005).
Talantov et al., “Novel Genes Associated with Malignant Melanoma but not Benign Melanocytic Lesions,”Clinical Cancer Research, vol. 11:7234-7242 (2005).
Trent et al., “Tumorigenic

Affiliated with

Also associated with

Rating

Melanoma gene signature does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Melanoma gene signature, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanoma gene signature will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4128548